Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
PVLA
Stock Latest News
The Fly
Palvella Therapeutics added to Russell 3000, Russell 2000 Indexes
3d ago
PVLA
Premium
Ratings
Palvella Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Trial and Market Potential
9d ago
PVLA
Premium
The Fly
Palvella Therapeutics completes enrollment in Phase 3 SELVA trial
10d ago
PVLA
Premium
The Fly
Palvella Therapeutics granted sixth U.S. patent covering rapamycin
15d ago
PVLA
Premium
Company Announcements
Palvella Therapeutics Holds Annual Stockholders Meeting
22d ago
8K
PVLA
Premium
The Fly
Palvella Therapeutics receives initial proceeds from FDA Orphan Products grant
24d ago
PVLA
Premium
Company Announcements
Palvella Therapeutics Advances in Rare Skin Disease Therapies
1M ago
PVLA
Premium
The Fly
Palvella Therapeutics appoints Kline as Chief Commercial Officer
1M ago
PVLA
Premium
Ratings
Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position
2M ago
PVLA
Premium
The Fly
Palvella Therapeutics price target lowered to $52 from $53 at Canaccord
2M ago
PVLA
Premium
Ratings
Promising Outlook for Palvella Therapeutics: Buy Rating Backed by Strong Financials and Innovative QTORIN Platform
2M ago
PVLA
Premium
Company Announcements
Palvella Therapeutics Reports Strong Q1 Financial Results
2M ago
8K
PVLA
Premium
The Fly
Palvella Therapeutics reports Q1 EPS (74c), consensus ($1.32)
2M ago
PVLA
Premium
The Fly
Palvella Therapeutics expects cash to fund operations into H2 of 2027
2M ago
PVLA
Premium
Ratings
Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics
2M ago
PVLA
Premium
The Fly
Palvella Therapeutics granted U.S patent for QTORIN Rapamycin
2M ago
PVLA
Premium
The Fly
Palvella Therapeutics announces data on QTORIN rapamycin
3M ago
PVLA
Premium
The Fly
Palvella Therapeutics initiated with a Buy at Chardan
3M ago
PVLA
Premium
The Fly
Palvella Therapeutics price target raised to $53 from $39 at Canaccord
3M ago
PVLA
Premium
Ratings
Palvella Therapeutics: Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating
3M ago
PVLA
Premium
Ratings
High-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment
3M ago
PVLA
Premium
The Fly
Palvella Therapeutics price target raised to $70 from $30 at Cantor Fitzgerald
3M ago
PVLA
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
